Key result
Interferon-γ shows promise as adjunctive therapy against nonviral intracellular infections in specific immunodeficiencies.
Why the study?
Prevention of morbidity and mortality from infectious diseases requires a better understanding of protective immunity, motivating an assessment of IFN-gamma biology and its prospects as a therapeutic against microbial pathogens.
Does interferon-γ improve outcomes in patients with infectious diseases?
Does interferon-γ improve outcomes in patients with infectious diseases?
Answers are grounded in this paper and cite their sources.
This review highlights the indispensable role of interferon-γ in human defense against intracellular pathogens and its potential therapeutic applications.
Infectious diseases continue to claim many lives. Prevention of morbidity and mortality from these diseases would benefit not just from new medicines and vaccines but also from a better understanding of what constitutes protective immunity. Among the major immune signals that mobilize host defense against infection is interferon- γ (IFN- γ ), a protein secreted by lymphocytes. Forty years ago, IFN- γ was identified as a macrophage-activating factor, and, in recent years, there has been a resurgent interest in IFN- γ biology and its role in human defense. Here we assess the current understanding of IFN- γ , revisit its designation as an “interferon,” and weigh its prospects as a therapeutic against globally pervasive microbial pathogens.
No takes yet. Share an insight, caveat, or question.
Casanova et al. (2024) conducted a review in Infectious diseases. Interferon-γ was evaluated. Interferon-γ plays an indispensable role in human host defense against nonviral intracellular pathogens and shows promise as an adjunctive therapy for specific immunodeficient patients.
Synapse has enriched 10 related papers. Consider them for comparative context: